Seattle Genetics (SGEN) Announces FDA Approval of ADCETRIS as Classical HL Treatment in Certain Patients
Tweet Send to a Friend
Seattle Genetics (NASDAQ: SGEN) announced that the U.S. Food and Drug Administration (FDA) has approved ADCETRIS (brentuximab vedotin) for the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
